Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francis Giles

Showing results (31-40 of 174) with videos related to

Pageof 18
Sort By:
Cancer Immunology, Immunotherapy : CII|October 21, 2016
A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetesYoung Kwang Chae, Lauren Chiec, Nisha Mohindra, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2009
Cdc7 kinase - a new target for drug developmentRonan Swords, Devalingam Mahalingam, Michael O'Dwyer, et al.
Leukemia Research|May 4, 2004
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemiaPatricia Ault, Hagop Kantarjian, Mary Alma Welch, et al.
Cancer|March 15, 2008
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulationsTai-Sung Lee, Steven J Potts, Hagop Kantarjian, et al.
Leukemia & Lymphoma|October 11, 2007
A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometryJoanne Bareng, Iman Jilani, Mercedes Gorre, et al.
Plos One|August 23, 2011
Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modelingTai-Sung Lee, Hagop Kantarjian, Wanlong Ma, et al.
European Journal of Clinical Investigation|May 3, 2012
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemiaFrancis Giles, François-Xavier Mahon, Bjorn Gjertsen, et al.
Experimental Hematology|April 6, 2010
Circulating CD33 and its clinical value in acute leukemiaAdam Abdool, Chen-Hsiung Yeh, Hagop Kantarjian, et al.
Molecular Cancer Therapeutics|December 6, 2008
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulationsTai-Sung Lee, Wanlong Ma, Xi Zhang, et al.
Current Drug Targets|October 29, 2009
Targeting sarcomas: novel biological agents and future perspectivesDevalingam Mahalingam, Alain Mita, Kamalesh Sankhala, et al.
Pageof 18

Showing results (31-40 of 174) with videos related to

Sort By:
Pageof 18
Cancer Immunology, Immunotherapy : CII|October 21, 2016
A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetesYoung Kwang Chae, Lauren Chiec, Nisha Mohindra, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2009
Cdc7 kinase - a new target for drug developmentRonan Swords, Devalingam Mahalingam, Michael O'Dwyer, et al.
Leukemia Research|May 4, 2004
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemiaPatricia Ault, Hagop Kantarjian, Mary Alma Welch, et al.
Cancer|March 15, 2008
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulationsTai-Sung Lee, Steven J Potts, Hagop Kantarjian, et al.
Leukemia & Lymphoma|October 11, 2007
A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometryJoanne Bareng, Iman Jilani, Mercedes Gorre, et al.
Plos One|August 23, 2011
Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modelingTai-Sung Lee, Hagop Kantarjian, Wanlong Ma, et al.
European Journal of Clinical Investigation|May 3, 2012
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemiaFrancis Giles, François-Xavier Mahon, Bjorn Gjertsen, et al.
Experimental Hematology|April 6, 2010
Circulating CD33 and its clinical value in acute leukemiaAdam Abdool, Chen-Hsiung Yeh, Hagop Kantarjian, et al.
Molecular Cancer Therapeutics|December 6, 2008
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulationsTai-Sung Lee, Wanlong Ma, Xi Zhang, et al.
Current Drug Targets|October 29, 2009
Targeting sarcomas: novel biological agents and future perspectivesDevalingam Mahalingam, Alain Mita, Kamalesh Sankhala, et al.
Pageof 18